References
- Danese E, Montagnana M, Johnson JA, et al. (2012). Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92:746–56
- Edson KZ, Prasad B, Unadkat JD, et al. (2013). Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 52:8276–85
- Hashizume T, Imaoka S, Mise M, et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298–304
- Hashizume T, Mise M, Matsumoto S, et al. (2001). A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798–805
- Hsu MH, Savas Ü, Griffin KJ, Johnson EF. (2007). Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39:515–38
- Jin Y, Zollinger M, Borell H, et al. (2011). CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 39:191–8
- Kalsotra A, Strobel HW. (2006). Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther 112:589–611
- King LM, Ma J, Srettabunjong S, et al. (2002). Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 61:840–52
- Liu KH, Kim MG, Lee DJ, et al. (2006). Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793–7
- Matsumoto S, Hirama T, Matsubara T, et al. (2002). Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240–5
- McDonald MG, Rieder MJ, Nakano M, et al. (2009). CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337–46
- Michaels S, Wang MZ. (2014). The revised human liver cytochrome P450 “pie”: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos 42:1241–51
- Nakamura K, Obayashi K, Araki T, et al. (2012). CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther 37:481–5
- Nelson DR, Zeldin DC, Hoffman SM, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18
- Nishimuta H, Sato K, Mizuki Y, et al. (2011). Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26:300–6
- Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8
- Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6
- Perrett HF, Barter ZE, Jones BC, et al. (2007). Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 35:1733–6
- Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
- Takeuchi F, McGinnis R, Bourgeois S, et al. (2009). A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433
- Uehara S, Murayama N, Nakanishi Y, et al. (2014). Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica 44:769–74
- Uehara S, Murayama N, Nakanishi Y, et al. (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654–61
- Uno Y, Hosaka S, Matsuno K, et al. (2007). Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98–105
- Uno Y, Iwasaki K, Yamazaki H, Nelson DR. (2011a). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346–61
- Uno Y, Matsuno K, Nakamura C, et al. (2011b). Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci 73:487–90
- Uno Y, Matsushita A, Osada N, et al. (2010). Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 38:209–14
- Uno Y, Osada N. (2011). CpG site degeneration triggered by the loss of functional constraint created a highly polymorphic macaque drug-metabolizing gene, CYP1A2. BMC Evol Biol 11:283
- Uno Y, Sakuraba H, Uehara S, et al. (2009). A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism. Drug Metab Dispos 37:14–17
- Wang MZ, Wu JQ, Bridges AS, et al. (2007). Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos 35:2067–75
- Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460–8
- Yamazaki H, Okayama A, Imai N, et al. (2006). Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 36:1201–9